Advanced search

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)

(2011) LANCET. 377(9772). p.1154-1154
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Salles, Gilles, John Francis Seymour, and Fritz Offner. 2011. “Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab Plus Chemotherapy (PRIMA): a Phase 3, Randomised Controlled Trial (vol 377, Pg 42, 2011).” Lancet.
APA
Salles, Gilles, Seymour, J. F., & Offner, F. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011). LANCET.
Vancouver
1.
Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011). LANCET. 2011. p. 1154–1154.
MLA
Salles, Gilles, John Francis Seymour, and Fritz Offner. “Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab Plus Chemotherapy (PRIMA): a Phase 3, Randomised Controlled Trial (vol 377, Pg 42, 2011).” LANCET 2011 : 1154–1154. Print.
@misc{2005648,
  author       = {Salles, Gilles and Seymour, John Francis and Offner, Fritz},
  issn         = {0140-6736},
  language     = {eng},
  number       = {9772},
  pages        = {1154--1154},
  series       = {LANCET},
  title        = {Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)},
  volume       = {377},
  year         = {2011},
}

Web of Science
Times cited: